Progressive CD4^+^ T cell depletion is a hallmark of HIV and pathogenic simian immunodeficiency virus (SIV) infection, and it is thought to play a primary role in mediating the immunodeficiency that characterizes AIDS ([@bib6]). Although these viruses target and destroy CD4^+^ T cells, the pathophysiology of the slow progressive depletion mediated by typical CCR5-tropic HIV/SIV involves a complex interplay between CD4^+^ T cell destruction (both direct killing by viral infection and indirect killing of uninfected cells by activation-related apoptosis) and regeneration, the latter initiated by both homeostatic mechanisms and immune activation ([@bib10]; [@bib4]). Massive viral replication in primary infection preferentially targets CCR5-expressing CD4^+^ transitional effector memory T cells (T~TrEM~) and fully differentiated effector memory T cells (T~EM~), causing profound depletion of these CD4^+^ T cell populations in extra-lymphoid effector sites ([@bib3]; [@bib16]). However, CCR5-nonexpressing secondary lymphoid tissue--based central memory CD4^+^ T cells (T~CM~) are relatively spared from this initial destruction and provide precursors for both their own homeostasis and partial CD4^+^ T~TrEM~ and T~EM~ regeneration ([@bib23]; [@bib20]; [@bib9]; [@bib15]). In the absence of such CD4^+^ T~TrEM~ and T~EM~ regeneration, SIV-infected rhesus macaques (RMs) manifest rapid progression to AIDS, whereas in its presence, RMs survive into chronic infection, maintaining sufficient CD4^+^ T cell effector function to hold opportunistic infections (OIs) at bay ([@bib23]; [@bib20]; [@bib9]). This tenuous immune competence is unstable, as over time, lymphoid microenvironments are destroyed ([@bib32]) and CD4^+^ T~CM~ populations progressively decline, reducing CD4^+^ T~TrEM~ and T~EM~ production until these effector populations fall below a crucial threshold associated with the onset of AIDS ([@bib20]). Thus, although CD4^+^ T~TrEM~ and T~EM~ comprise the proximate effectors that directly mediate most of the immunological functions of CD4^+^ T cell lineage, the progressive homeostatic failure of the T~CM~ population and the consequent inability of this population to produce sufficient numbers of T~TrEM~ and T~EM~ appear to play a major role in determining the tempo disease progression to AIDS.

In RMs infected with pathogenic, CCR5-tropic SIV, CD4^+^ T~TrEM~ and T~EM~ populations can collapse and overt AIDS can ensue in the presence of essentially normal CD4^+^ naive T cell (T~N~) populations ([@bib23]; [@bib20]), suggesting that T~N~ are not able to directly support T~TrEM~ and T~EM~ regeneration. However, it has been suggested that CD4^+^ T~CM~ population stability is dependent on continuous recruitment of new cells from the T~N~ pool ([@bib19]). In this regard, the CD4^+^ T~TrEM~ and T~EM~ most relevant to HIV/SIV infection and AIDS are those specific for HIV/SIV itself and for the pathogens responsible for OIs, which are either persistent or environmentally ubiquitous agents that are continuously or periodically available to drive de novo T~M~ production from T~N~ precursors ([@bib30]). Alternatively, T~CM~ include cells with stem-like qualities ([@bib8]), and it is possible that CD4^+^ T~CM~ homeostasis is more dependent on proliferation and survival of T~CM~ populations established before infection.

To determine the role of CD4^+^ T~N~ recruitment in CD4^+^ T~CM~ population stability in progressive SIV infection, we developed a new RM model in which the CD4^+^ T~N~ compartment of healthy juvenile RMs is specifically, permanently, and profoundly depleted. Such CD4^+^ T~N~-depleted RMs were created by thymectomizing juvenile animals, followed by treatment with the depleting anti-CD4 huOKT4 mAb ([@bib7]), and then allowing ∼7 mo for maximal CD4^+^ T~M~ regeneration. Control animals (CD4^+^ T~N~-repleted RMs) were sham-thymectomized, but otherwise treated identically. CD4^+^ T~M~ regeneration was comparable in both groups, but only the sham-thymectomized group manifested CD4^+^ T~N~ recovery. Strikingly, upon infection with the SIVmac239, we observed no significant differences between these groups in the kinetics and magnitude of SIV replication, CD4^+^ T~M~ decline, or time to AIDS, despite a marked attenuation of the SIV-specific CD4^+^ T cell response and significant impairments in the development of both the SIV-specific CD8^+^ T cell and Ab responses in the CD4^+^ T~N~-depleted RMs. These data demonstrate that the CD4^+^ T~N~ compartment is not required for CD4^+^ T~M~ homeostasis/regeneration in pathogenic SIV infection, and they confirm the essential role of CD4^+^ T~CM~ homeostasis in AIDS pathogenesis.

RESULTS AND DISCUSSION
======================

Establishment of permanent selective CD4^+^ T~N~ cell deficiency by anti-CD4 mAb-mediated CD4^+^ T cell depletion of thymectomized juvenile RMs
-----------------------------------------------------------------------------------------------------------------------------------------------

Previous work has demonstrated that abrogation of thymopoiesis---and, consequently, de novo T~N~ production---by preinfection thymectomy does not have a significant impact on the pathogenesis of SIV infection ([@bib1]). However, thymectomy would not affect previously established T~N~, and the RMs in these studies would have had a large pool of CD4^+^ T~N~ at the time of SIV infection that would have been capable of supporting CD4^+^ T~M~ homeostasis post infection (pi). To more rigorously assess the ability of CD4^+^ T~N~ to contribute to CD4^+^ T~M~ homeostasis in the setting of pathogenic SIV infection, we sought to create an RM model in which the CD4^+^ T~N~ compartment is selectively ablated. We based our approach on the hypothesis that the thymus is the only significant source of de novo T~N~ production in primates, and on previous observations that CD4^+^ T~N~ populations in euthymic juvenile RMs reconstitute after efficient depletion by treatment with mAb huOKT4 ([@bib1]; [@bib7]). Our strategy was to perform thymectomy or sham surgery on groups of 3--5-yr-old RMs, followed by mAb huOKT4-mediated CD4^+^ lymphocyte depletion and postdepletion recovery to a stable endpoint ([Fig. 1 A](#fig1){ref-type="fig"}). We expected CD4^+^ T~N~, but not CD4^+^ T~M~, reconstitution to depend on the presence of a functioning thymus.

![**Thymectomy abrogates CD4^+^ T~N~ recovery after antibody-mediated CD4^+^ T cell depletion.** (A) Schematic representation of the experimental protocol used in this study. (B--J) Analysis of CD4^+^ and CD8^+^ T~N~ (dashed lines) and T~M~ (solid lines) population dynamics after mAb huOKT4A treatment in RMs with complete initial CD4^+^ T cell depletion in blood that were previously subjected to thymectomy (red, *n* = 9) versus sham surgery (blue, *n* = 9). Results (mean + SEM) are shown as percentage of baseline, or for percentage of Ki-67^+^, change (Δ) from baseline (see Materials and methods). Note that T cells in BAL and small intestinal mucosa are essentially all T~M~ ([@bib25]). The significance of differences in these parameters between the thymectomized and sham-treated groups at day 238 (day 105 for small intestinal mucosa cells) after first mAb dose was assessed as described in the Materials and methods (significant p-values shown; NS, nonsignificant). (K) Comparison of the frequency of RhCMV-responsive cells within the CD4^+^ memory populations of blood and BAL at day 238 after depletion. Shown are box plots, with boxes and whiskers indicating interquartile ranges (25^th^--75^th^ percentiles) and 10^th^--90^th^ percentile values, respectively. (L) Analysis of CD4^+^ T~N~ (blue) and CD4^+^ T~M~ (red) dynamics (absolute counts and proliferative fraction; mean + SEM) in three thymectomized RMs with incomplete initial CD4^+^ T cell depletion in blood (mean of 95% at day 21) after mAb huOKT4A treatment. (M) Flow cytometric profiles of blood and peripheral LN T~N~ versus T~M~ subsets from representative thymectomized and sham-treated RMs before and after complete CD4^+^ T cell depletion. The CD28 versus CD95 profiles shown were gated on CD3^+^/CD4^+^ small lymphocytes with red lines delineating the position of the T~N~ cluster. Multiparameter analysis (see Materials and methods) was used for the actual quantification of T~N~ versus T~M~, with the percentage of T~N~ shown in red.](JEM_20112071_Fig1){#fig1}

As shown in [Fig. 1 (B--D)](#fig1){ref-type="fig"}, 18 RMs (9 thymectomized and 9 sham-treated) receiving mAb huOKT4 treatment (out of a total of 26, with 13 in each group) achieved complete depletion of CD4^+^ T~N~ and T~M~ in blood and CD4^+^ T~N~ in LN through day 35 after treatment. As expected, CD4^+^ T~N~ numbers subsequently rebounded in blood and LN of sham-treated controls, but not in the thymectomized RMs. Regenerating CD4^+^ T~N~ in the blood of the sham-treated RMs showed a relatively small increase in their proliferative fraction (Ki-67^+^; [@bib25]) from before depletion ([Fig. 1 E](#fig1){ref-type="fig"}, dashed line), consistent with the thymus (rather than peripheral regeneration) being the primary source of CD4^+^ T~N~ recovery in these RMs. After mAb huOKT4 treatment, CD4^+^ T~M~ were incompletely depleted in LN ([Fig. 1 D](#fig1){ref-type="fig"}) and effector sites (lung airspace and small intestinal lamina propria; [Fig. 1, F and G](#fig1){ref-type="fig"}) of both thymectomized and sham-treated RMs, providing a substrate for subsequent T~M~ regeneration. Indeed, in both RM groups, CD4^+^ T~M~ reappeared in the blood at ∼35 d after depletion and recovered to a similar degree (\>50% of pre-depletion levels) over the subsequent 120 d ([Fig. 1 C](#fig1){ref-type="fig"}). Both groups also manifested stabilization of CD4^+^ T~M~ recovery at ∼75% of pre-depletion levels in the effector sites ([Fig. 1, F and G](#fig1){ref-type="fig"}). CD4^+^ T~M~ recovery was clearly associated with peripheral homeostatic expansion, as the fraction of circulating CD4^+^ T~M~ expressing Ki-67 was dramatically increased from pretreatment baseline levels during early recovery, falling back to near baseline levels upon stabilization of CD4^+^ T~M~ numbers at 140--160 d after depletion ([Fig. 1 E](#fig1){ref-type="fig"}, solid lines). Both thymectomized and sham-treated RMs manifested similar frequencies of RhCMV-specific CD4^+^ T cells in blood and lung airspace after recovery ([Fig. 1 K](#fig1){ref-type="fig"}), in keeping with the essentially equivalent CD4^+^ T~M~ regeneration in these RMs.

To ascertain whether homeostatic activation and expansion of CD4^+^ T~N~ with memory conversion contributed to CD4^+^ T~M~ recovery ([@bib28]), we analyzed CD4^+^ T~N~ and T~M~ dynamics in three thymectomized RMs in which CD4^+^ T cell depletion in blood fell just short of completion, allowing analysis throughout the regeneration period ([Fig. 1 L](#fig1){ref-type="fig"}). After treatment of these RMs, residual CD4^+^ T~M~ showed regeneration similar to that previously described for the RMs with complete depletion, associated with a marked increase in proliferative fraction, whereas residual CD4^+^ T~N~ showed (at all time points) very limited regeneration associated with much smaller changes in proliferative fraction. As proliferating T~N~ serve as the substrate for T~N~-derived pseudo-memory differentiation, and as this process might be expected to deplete the phenotypically defined T~N~ cells in the absence of thymic renewal, these data argue against a significant contribution of this process to CD4^+^ T~M~ recovery under the conditions of this experiment.

HuOKT4 mAb treatment had little effect on CD8^+^ T~N~ numbers in blood in either RM group ([Fig. 1 H](#fig1){ref-type="fig"}), whereas CD8^+^ T~M~ from both groups displayed a variable, modest increase in numbers in blood that was associated with a transient increase in proliferative fraction, consistent with a response to common homeostatic cytokines ([Fig. 1, I and J](#fig1){ref-type="fig"}). Overall, these data demonstrate the ability to generate RMs with profound systemic CD4^+^ T~N~ cell deficiency (CD4^+^ T~N~-depleted), as well as a matched control group that has undergone similar treatment but has regenerated a CD4^+^ T~N~ compartment that is at, or very near, pretreatment baseline levels (CD4^+^ T~N~-repleted; [Fig. 1 M](#fig1){ref-type="fig"}).

SIV replication dynamics and the development of SIV-specific adaptive immunity in CD4^+^ T~N~-depleted versus -repleted RMs
---------------------------------------------------------------------------------------------------------------------------

Reconstitution of all CD4^+^ T cell subsets reached a plateau in both CD4^+^ T~N~-depleted and -repleted RM cohorts at ∼140 dafter depletion ([Fig. 1](#fig1){ref-type="fig"}) and, after documenting an additional 95 d of population stability, both cohorts (*n* = 9 each) were challenged with highly pathogenic SIVmac239 by i.v. injection. Our strategy was to allow the infection to proceed without interference for 70 d to allow comparison of the ability of each cohort to: establish plasma viral load (pvl) set-point; develop adaptive SIV-specific immunity; and stabilize early plateau-phase CD4^+^ T~M~ population dynamics. At day 70 pi, we administered the anti-retroviral drugs tenofovir (30 mg/kg/d) and emtricitabine (50 mg/kg/d) to assess the regenerative potential of CD4^+^ T~M~ associated with (partial) control of viral replication. These drugs were discontinued at day 154 pi, and the cohorts were subsequently compared for viral replication and lymphocyte population dynamics until the onset of clinical AIDS or for 211 d of untreated chronic infection (1 yr of infection overall; [Fig. 1 A](#fig1){ref-type="fig"}).

We also analyzed a contemporaneous group of six unmanipulated RMs given the same SIVmac239 challenge and followed for key parameters of infection through day 70 pi, so as to determine whether the sham surgery and/or the subsequent huOKT4 treatment and recovery from that treatment of the CD4^+^ T~N~-repleted control group affected the ability of these RMs to handle or respond to SIVmac239 infection. As shown in [Fig. 2 A](#fig2){ref-type="fig"}, this comparison demonstrated no significant differences between the unmanipulated RMs and the CD4^+^ T~N~-repleted RM cohort with respect to: peak and early plateau pvl; CD4^+^ T~M~ depletion in blood and bronchoalveolar lavage lymphocytes (BALs) at day 70 pi; the increase in CD4^+^ T~M~ proliferative fraction (Ki-67^+^) from baseline to day 70; and development of SIV-specific CD8^+^ T cell responses.

![**CD4^+^ T~N~-deficient RMs display SIV replication dynamics similar to control RMs despite attenuated SIV-specific T cell and Ab responses.** (A) Comparison of pvl, CD4^+^ T~M~ depletion, CD4^+^ T~M~ proliferative responses, and the magnitude of SIV-specific CD8^+^ T cell responses at day 70 pi between the CD4^+^ T~N~ -repleted control group (*n* = 9) and unmanipulated RMs (*n* = 6) challenged with the same SIVmac239 virus. Shown are box plots, with boxes and whiskers indicating interquartile ranges (25^th^--75^th^ percentiles) and 10^th^--90^th^ percentile values, respectively. Significance of differences in these parameters between groups was assessed as described in the Materials and methods (NS, nonsignificant). (B--G) Comparison of the indicated parameters (mean + SEM) over the course of SIVmac239 infection between the CD4^+^ T~N~-depleted and CD4^+^ T~N~-repleted groups (*n* = 9 each). The period over which all RMs received ART (day 70--156 pi) is shown in gray. The inset in E shows the percentage of RMs in the CD4^+^ T~N~-depleted (red) and T~N~-repleted (blue) RM groups that displayed a measureable anti-SIVenv neutralizing Ab response (e.g., seroconverted) before ART. Differences in these parameters between the CD4^+^ T~N~-depleted and CD4^+^ T~N~-repleted groups were statistically analyzed as described in the Materials and methods, with brackets indicating time points that were grouped together for analysis (significant p-values shown).](JEM_20112071_Fig2){#fig2}

At the end of the recovery period after huOKT4 treatment, the CD4^+^ T~N~-depleted cohort manifested almost a complete absence of circulating CD4^+^ T~N~ cells. Importantly, no CD4^+^ T~N~ regeneration was observed throughout the entire course of SIV infection in the CD4^+^ T~N~-depleted cohort, in sharp contrast to the CD4^+^ T~N~-repleted RMs ([Fig. 2 B](#fig2){ref-type="fig"}). CD4^+^ T~N~ lack CCR5 expression, and are thus not primary targets of CCR5-tropic SIV ([@bib23]). Therefore, given the essentially equivalent CD4^+^ T~M~ populations in the CD4^+^ T~N~-depleted and -repleted cohorts ([Fig. 1](#fig1){ref-type="fig"}), it is not surprising that the absence of CD4^+^ T~N~ in the former group had no effect on peak pvl ([Fig. 2 C](#fig2){ref-type="fig"}). More surprising was the observation that early plateau- and chronic-phase pvl were also not significantly different between the CD4^+^ T~N~-depleted and -repleted groups ([Fig. 2 C](#fig2){ref-type="fig"}), despite the facts that SIV-specific CD4^+^ T cell responses were essentially absent in CD4^+^ T~N~-depleted RMs during acute infection ([Fig. 2 D](#fig2){ref-type="fig"}), and that only 11% of these RMs (vs. 78% of the CD4^+^ T~N~-repleted group) showed the development of SIVenv-specific Abs by day 70 pi ([Fig. 2 E](#fig2){ref-type="fig"}, inset). The magnitude of the SIV-specific CD8^+^ T cell response in blood also tended to be lower in the CD4^+^ T~N~-depleted RMs than in the CD4^+^ T~N~-repleted controls, but this difference achieved statistical significance only during anti-retroviral therapy (ART; [Fig. 2 F](#fig2){ref-type="fig"}). However, a significant difference in the frequency of SIV-specific CD8^+^ T cells in CD4^+^ T~N~-depleted versus -repleted cohorts was observed in BAL during early plateau phase, as well as after ART cessation ([Fig. 2 G](#fig2){ref-type="fig"}), suggesting that SIV-specific CD8^+^ T cell responses were compromised in the absence of CD4^+^ T~N~.

It is noteworthy that small SIV-specific CD4^+^ T cell responses were detected over time in the CD4^+^ T~N~-depleted RMs ([Fig. 2 D](#fig2){ref-type="fig"}), suggesting that in the context of persistent Ag exposure, either residual CD4^+^ T~N~ or cross-reactive CD4^+^ T~M~ ([@bib27]) can eventually be recruited to generate specific CD4^+^ T cell responses in CD4^+^ T~N~-depleted RMs. ART was associated with development of SIVenv-specific Ab responses in those CD4^+^ T~N~-depleted RMs that had failed to develop these Abs before ART, although this occurred before first detection of SIV-specific CD4^+^ T cells ([Fig. 2, D and E](#fig2){ref-type="fig"}). Titers of SIVenv-specific Abs were ∼1 log higher in the CD4^+^ T~N~-repleted RMs compared with the CD4^+^ T~N~-depleted RMs throughout the course of the study, but these differences did not achieve statistical significance ([Fig. 2 E](#fig2){ref-type="fig"}).

The severe impairment of the SIV-specific CD4^+^ T cell response in CD4^+^ T~N~-depleted versus -repleted RMs and the associated effects on the development of SIV-specific Ab and CD8^+^ T cell responses confirms the stringency of CD4^+^ T~N~ depletion in the former group (reducing SIV-specific CD4^+^ T~N~ precursors below the threshold needed for a normal response) and is consistent with the previously well described importance of CD4^+^ helper T cells to other aspects of the adaptive immune response ([@bib2]; [@bib17]). It is, however, remarkable that these deficits in the adaptive immune response to SIV had very little effect on SIV replication dynamics in either early plateau phase or post-ART chronic phase. This observation is consistent with the idea that absent CD8^+^ T cell responses restricted by protective class I MHC alleles, adaptive immunity has only a limited influence on the course of highly pathogenic SIV infection of unvaccinated RMs ([@bib24]). We would also note, however, that although the postpeak drop in pvl from peak to early plateau phase was relatively modest in both the CD4^+^ T~N~-depleted and -repleted groups reported here, it was still significantly greater than RMs that have been experimentally depleted of CD8^+^ lymphocytes by anti-CD8 mAb administration during acute SIVmac239 infection, where there is typically no drop in pvl from peak levels and RMs rapidly progress to AIDS ([@bib21]). This difference, reflecting limited CD8^+^ lymphocyte-dependent viral control, could be mediated by the relatively modest SIV-specific CD8^+^ T cell responses observed in our RMs (including responses developing in the absence of CD4^+^ T cell help) or, potentially, by non--Ag-specific (innate) functions of CD8^+^ lymphocytes (T cells and/or NK cells; [@bib21]).

CD4^+^ T~M~ homeostasis and disease progression in SIV-infected RMs with and without a CD4^+^ T~N~ compartment
--------------------------------------------------------------------------------------------------------------

Given the statistically equivalent viral dynamics manifested by the CD4^+^ T~N~-depleted and -repleted cohorts throughout the course of infection (both on and off ART; [Fig. 2 C](#fig2){ref-type="fig"}), it is likely that the direct and indirect stress of pathogenic SIV infection on CD4^+^ T~M~ homeostasis (e.g., direct viral killing or immune activation-mediated destruction and dysregulation of the CD4^+^ T~M~ themselves or their supporting microenvironments; [@bib10]) was comparable for both groups. Therefore, the extent to which the CD4^+^ T~M~ compartment depends on T~N~ recruitment in the face of this stress would be reflected by the relative ability of CD4^+^ T~N~-depleted RMs to maintain overall and proliferating CD4^+^ T~M~ populations compared with the CD4^+^ T~N~-repleted RMs. Strikingly, we found no evidence of compromised homeostasis of any CD4^+^ T~M~ subset in the absence of a CD4^+^ T~N~ compartment, including T~CM~, T~TrEM~, T~EM~, and regulatory (CD25^+^/FoxP3^+^) T~M~ populations ([Fig. 3, A--D](#fig3){ref-type="fig"}). The kinetics and extent of CD4^+^ T~M~ loss in blood (all subsets) and BAL in early infection (through day 70 pi) were essentially identical between the CD4^+^ T~N~-depleted and --repleted groups ([Fig. 3, A and C](#fig3){ref-type="fig"}). Interestingly, the increase in CD4^+^ T~M~, T~CM~, and T~TrEM~ numbers after partial inhibition of viral replication with tenofovir and emtricitabine was actually significantly higher in the CD4^+^ T~N~-depleted group, perhaps as the result of an increased availability of homeostatic cytokines such as IL-7 in the absence of a CD4^+^ T~N~ population ([Fig. 3 A](#fig3){ref-type="fig"}). This difference was not maintained, however, as CD4^+^ T~M~ counts equalized between the study cohorts toward the end of ART and remained equivalent during post-ART chronic infection ([Fig. 3 A](#fig3){ref-type="fig"}). The infection-associated increase in the proliferative fraction of circulating CD4^+^ T~CM~ (but not other T~M~ subsets) was significantly, albeit modestly, lower in the CD4^+^ T~N~-depleted group in the early plateau phase of infection ([Fig. 3 B](#fig3){ref-type="fig"}, region a), perhaps as a result of the lack of an SIV-specific CD4^+^ T cell response in this group (which could have directly contributed to the proliferative fraction, as well as indirectly promoted nonspecific CD4^+^ T~CM~ proliferation via elaboration of IL-2). Given the stability of T~CM~ numbers and T~TrEM~ and T~EM~ production in CD4^+^ T~N~-depleted RMs during this time period ([Fig. 3, A and C](#fig3){ref-type="fig"}), this finding does not appear to reflect impaired CD4^+^ T~CM~ homeostasis. Moreover, the unimpaired capacity of the CD4^+^ T~CM~ (and other CD4^+^ T~M~ subsets) in CD4^+^ T~N~-depleted RMs to expand is demonstrated by the equivalently increased proliferative fraction of these cells in blood and LN after the initiation of ART ([Fig. 3, B and E](#fig3){ref-type="fig"}). Finally, CD8^+^ T~M~ dynamics in blood (absolute counts and proliferative fraction) were also statistically indistinguishable between the CD4^+^ T~N~-depleted and -repleted groups ([Fig. 3, F and G](#fig3){ref-type="fig"}).

![**CD4^+^ T~N~ deficiency does not compromise CD4^+^ T~M~ homeostasis in progressive and partially suppressed SIV infection.** (A--D) Comparison of the dynamics (absolute counts and proliferative fraction; mean + SEM) of overall CD4^+^ T~M~ and the T~CM~, T~TrEM~, and T~EM~ subsets in blood, the percentage of CD4^+^ of total CD3^+^ (memory) T cells in BAL, and absolute counts of CD4^+^ T~M~ with a regulatory phenotype (CD25^+^/FoxP3^+^) in blood of CD4^+^ T~N~-depleted (red, *n* = 9) versus -repleted RMs (blue, *n* = 9) over the course of SIV infection (as in [Fig. 1 A](#fig1){ref-type="fig"}). The significance of differences in these parameters between RM groups in the indicated regions was assessed as described in the Materials and methods (significant p-values shown; NS, nonsignificant). (E) Comparison of the change in the percentage of Ki-67^+^ CD4^+^ T~M~ in peripheral LN of CD4^+^ T~N~-depleted versus --repleted RMs between days 70 (ART day 0) and 73 (3 d after ART). Note that the increase in the percentage of Ki-67^+^ cells from day 70 to 73 was significant in both groups (p-values shown), but the magnitude of this increase (Δ%Ki-67) was not different between groups. (F and G) Comparison of the dynamics of CD8^+^ T~M~ in the blood of CD4^+^ T~N~-depleted versus --repleted RMs over the course of SIV infection (mean + SEM), with statistical analysis of the indicated regions.](JEM_20112071_Fig3){#fig3}

Thus, profound CD4^+^ T~N~ depletion did not impair either CD4^+^ T~CM~ homeostasis or CD4^+^ T~TrEM~ and T~EM~ production in SIV-infected RMs, which are both parameters whose failure has been previously associated with progression to AIDS ([@bib23]; [@bib20]; [@bib9]). To evaluate whether CD4^+^ T~N~ cell deficiency was associated with accelerated disease progression, we performed statistical analysis of Kaplan-Meier plots of the time to development of end-stage (AIDS compatible) disease by log-rank test. As shown in [Fig. 4 A](#fig4){ref-type="fig"}, we found no significant difference in the time to end-stage disease between the CD4^+^ T~N~-depleted and -repleted groups. Pathological findings were consistent with end-stage simian AIDS in all RMs clinically progressing to AIDS during the study period, with no major differences in disease manifestations between groups ([Fig. 4 B](#fig4){ref-type="fig"}). At necropsy, LN of CD4^+^ T~N~-depleted RMs showed very few cells with a T~N~-compatible phenotype, in contrast to CD4^+^ T~N~-repleted RMs, which showed prominent CD4^+^ T~N~ populations ([Fig. 4 C](#fig4){ref-type="fig"}). To compare overall CD4^+^ T~M~ depletion in these two groups that had markedly different CD4^+^ T~N~ populations, we analyzed the ratio of CD4^+^ T~M~ to CD8^+^ T~M~ in both secondary lymphoid tissues (LN and spleen) and effector sites (BAL, liver, and small intestinal mucosa). As shown in [Fig. 4 D](#fig4){ref-type="fig"}, these ratios were not significantly different between the CD4^+^ T~N~-depleted and -repleted RMs, with both groups showing patterns typical of SIVmac239-induced AIDS (e.g., effector site CD4^+^ T~M~ depletion \> secondary lymphoid tissue CD4^+^ T~M~ depletion; [@bib20]). Thus, the presence or absence of CD4^+^ T~N~ had no measureable influence on the tempo of progression to overt immunodeficiency or the clinical/pathological manifestations of that immunodeficiency.

![**CD4^+^ T~N~ deficiency does not accelerate disease progression.** (A) Kaplan-Meier plot of the time to end-stage AIDS (day of disease mandated necropsy) for CD4^+^ T~N~-depleted (red, *n* = 9) versus -repleted RMs (blue, *n* = 9) over the 1 yr of follow-up. Log rank analysis indicated that rate of progression to AIDS between the two groups was not significantly different (P = 0.72). (B) Major pathological findings at necropsy of study RMs progressing to end-stage AIDS (*n* = 5 and 4 for CD4^+^ T~N~-depleted vs. -repleted RMs, respectively). (C) Flow cytometric profiles (as described in [Fig. 1 M](#fig1){ref-type="fig"}) of CD4^+^ T cell populations in blood and various LNs at necropsy of representative CD4^+^ T~N~-depleted (\#24273, progression to AIDS at day 190 pi) and CD4^+^ T~N~-repleted (\#25522, progression to AIDS at day 163 pi) RMs. The percentage of T~N~ of gated events (total CD4^+^ T) is shown in red in the bottom left. The percentage of CD4^+^ of total T cells is shown in black at the top right. (D) Comparison of CD4^+^/CD8^+^ ratios within the T~M~ populations in blood and selected secondary lymphoid tissues (axillary and inguinal LNs and spleen) and effector sites (liver, BAL, and small intestinal mucosa) of four of five CD4^+^ T~N~-depleted (red) and four of four CD4^+^ T~N~-repleted (blue) RMs studied at necropsy (one CD4^+^ T~N~-depleted RM could not be analyzed as a result of inadequate staining of cell preparations obtained at necropsy). Shown are box plots, with boxes and whiskers indicating interquartile ranges (25^th^--75^th^ percentiles) and 10^th^--90^th^ percentile values, respectively. Statistical analysis of differences in this parameter between groups was analyzed as described in the Materials and methods (NS, nonsignificant).](JEM_20112071_Fig4){#fig4}

The lack of effect of CD4^+^ T~N~ depletion on SIV control and disease progression in our study contrasts with the results of [@bib22], who found that all RMs infected with SIVmac251 45 d after mAb-mediated CD4^+^ T cell depletion manifested rapid disease progression (63 d median survival) with no postpeak decline in pvl. These different outcomes almost certainly reflect fundamental differences in the approaches used to hinder CD4^+^ T cell function in vivo. At the time of SIV infection, the CD4^+^ T~N~-depleted RMs described here were postregenerative, with baseline levels of CD4^+^ T~M~ turnover. In contrast, at the start of SIV infection, the CD4^+^ T cell--depleted RMs reported by [@bib22] manifested a regenerating CD4^+^ T cell compartment with a markedly elevated proliferative fraction (Ki-67^+^). In contrast to our findings of ablated SIV-specific CD4^+^ T cell responses and diminished SIV-specific Ab and CD8^+^ T cell responses in CD4^+^ T~N~-depleted RMs, [@bib22] reported unimpaired SIV-specific T cell (CD4^+^ and CD8^+^) and humoral immunity in their CD4^+^ T cell--depleted RMs compared with controls. These observations suggest that the rapid progression observed by [@bib22] is most likely a consequence of the regenerative state of the CD4^+^ T cells and/or the homeostatically activated lymphoid microenvironments in their RMs at the time of infection, rather than a direct result of deficient SIV-specific CD4^+^ T cell immunity.

Collectively, the data presented in this report indicate that CD4^+^ T~N~ are dispensable for CD4^+^ T~M~ homeostasis over the relatively short course of highly pathogenic CCR5-tropic SIV infection, a conclusion which strongly argues against both a continuous replenishment of CD4^+^ T~M~ by CD4^+^ T~N~ recruitment and a significant role for CD4^+^ T~N~ exhaustion in the pathogenesis of AIDS in SIV-infected RMs ([@bib19]). Our analysis also suggests that initial CD4^+^ T~M~ reconstitution in the setting of partially effective ART is CD4^+^ T~N~ independent and, in fact, might even be transiently enhanced by the absence of CD4^+^ T~N~ competition for trophic factors. These results imply that CD4^+^ T~N~ may be more of a bystander to AIDS pathogenesis than previously assumed, and that dysfunction of the mechanisms responsible for intrinsic homeostasis of the CD4^+^ T~CM~ compartment may play the dominant role in the immune degradation leading to AIDS, as well as in limitations in immune reconstitution after viral suppression. CD4^+^ T~N~ depletion is clearly a prominent feature of progressive HIV infection ([@bib13]; [@bib26]), and it remains possible that the lower viral replication rates and longer course of HIV infection in humans relative to SIV infection in RMs ([@bib14]) allows for CD4^+^ T~N~ to make a larger contribution to immune homeostasis in HIV infection than seen in the current study. However, it must be considered that the direct CD4^+^ T cell destruction, pathological immune activation, and microenvironmental destruction associated with HIV/SIV infection are detrimental to both CD4^+^ T~M~ and T~N~ homeostasis ([@bib6]; [@bib10]; [@bib13]; [@bib32]) and, thus, the degradation of CD4^+^ T~N~ homeostasis might closely correlate with AIDS progression or immune reconstitution without being the primary mechanistic factor that determines these outcomes. The determination of the relative contribution of the CD4^+^ T~N~ and T~M~ compartments to immune competence is of more than academic interest, as therapeutic approaches to optimally augment CD4^+^ T~N~ versus T~M~ regeneration are likely to be different. Our data would suggest that therapies directed at correcting disturbances in CD4^+^ T~CM~ homeostasis/regeneration might prove superior in maintaining or restoring effective immunity in HIV infection than therapies aimed at augmenting thymopoiesis or enhancing CD4^+^ T~N~ homeostasis.

MATERIALS AND METHODS
=====================

### Animals and viruses.

A total of 32 purpose-bred male juvenile RMs (*Macaca mulatta*) of Indian genetic background and free of Cercopithicine herpesvirus 1, D type simian retrovirus, simian T-lymphotrophic virus type 1, and SIV infection were used in this study. All animals were naturally infected with Rhesus CMV (RhCMV) before the start of the study. RMs with protective class 1 MHC alleles *Mamu* B\*08, *Mamu* B\*17, and *Mamu* A\*01 were excluded from the study. A total of 26 juvenile RMs (3--5 yr old) were subjected to surgical thymectomy or sham surgery (*n* = 13 per group) before receiving the CD4^+^ T cell--depleting anti-CD4 huOKT4A mAb ([@bib29]; [@bib7]). HuOKT4A mAb was i.v. administered two times at a dose of 50 mg/kg, 1 wk apart. Four RMs from each group were excluded from the SIV infection study as a result of incomplete CD4^+^ T cell depletion in blood, leaving *n* = 9 each in the CD4^+^ T~N~-depleted and CD4^+^ T~N~-repleted cohorts studied after SIV infection. Postdepletion data from three thymectomized RMs with high but incomplete depletion (mean of 95% at day 21) is shown to document CD4^+^ T~N~ and T~M~ dynamics in RMs in which these subsets can be analyzed throughout the regeneration period. Six additional RMs were studied as unmanipulated SIV-infected controls. RMs were infected with SIVmac239 via i.v. administration of 5-ng equivalents of SIV p27, corresponding to 2.7--3.0 × 10^4^ infectious centers, as previously described ([@bib23]). BALs were performed as previously described ([@bib23]). ART consisted of daily subcutaneous injections of 30 mg/kg 9-R-(2-phosphonomethoxypropyl) adenine (tenofovir) and 50 mg/kg β-2′,3′-dideoxy-3′-thia-5-fluorocytidine (emtricitabine). All RMs were studied at the Oregon National Primate Research Center in accordance with standards of the National Institutes of Health Guide for the Care and Use of Laboratory Animals under the approval of the Center's Animal Care and Use Committee. RMs that developed disease states that were not clinically manageable were euthanized in accordance with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. End-stage AIDS was defined by the presence of AIDS-defining OIs, wasting syndrome unresponsive to therapy, or non-Hodgkin's lymphoma ([@bib14]).

### Viral quantification.

Plasma SIV RNA was assessed using a real-time RT-PCR assay (threshold sensitivity = 30 SIV gag RNA copies/ml of plasma; inter-assay CV ≤ 25%), essentially as previously described ([@bib5]).

### MAbs.

MAbs L200 (CD4; AmCyan), SP34-2 (CD3; Alexa 700, Pacific blue), SK1 (CD8α; PerCP-Cy5.5), B56 (Ki-67; FITC), DX2 (CD95; PE, PE-Cy7), 2A3 (CD25; APC), 3A9 (CCR5; APC), and B27 (IFN-γ; APC) were obtained from BD. CD28.2 (PE-Texas red) and TP1.55.33 (CD69; PE-Texas red) were obtained from Beckman Coulter. mAb PCH101 (FoxP3; PE) and MAb111 (TNF; FITC; PE-Cy7) were obtained from eBioscience. mAb 150503 (anti-CCR7) was purchased as purified immunoglobulin from R&D Systems, conjugated to biotin using the EZ-Link Maleimide-PEO solid phase biotinylation kit (Thermo Fisher Scientific), and visualized with streptavidin--Pacific blue (Invitrogen). The depleting anti-CD4 huOKT4A mAb was provided by the National Institutes of Health Nonhuman Primate Reagent Resource Program.

### Immunological assays.

SIV-specific CD4^+^ and CD8^+^ T cell and RhCMV-specific CD4^+^ T cell responses were measured in mononuclear cell preparations from blood and tissues by flow cytometric intracellular cytokine analysis, as previously described ([@bib11]). In brief, sequential 15-mer peptides (overlapping by 11 amino acids) comprising the SIVmac239 Gag, Nef, Env, and Pol proteins or RhCMV viral lysates were used in the presence of costimulatory CD28 and CD49d monoclonal antibodies. Cells were incubated with antigen and costimulatory molecules alone for 1 h, followed by addition of Brefeldin A (Sigma-Aldrich) for an additional 8 h. Co-stimulation without antigen served as a background control. Cells were then stained with fluorochrome-conjugated monoclonal antibodies, flow cytometric data collected on an LSR II (BD), and data analyzed using the FlowJo software program (version 8.8.6; Tree Star). Response frequencies (CD69^+^/TNF^+^ and/or CD69^+^/IFN-γ^+^) were first determined in the overall CD4^+^ and CD8^+^ population and then memory corrected (with memory T cell subset populations delineated on the basis of CD28 and CD95 expression), as previously described ([@bib12]). Neutralizing Abs against tissue culture-adapted SIVmac251 were measured in luciferase reporter gene assays using the TZM-bl cells for tissue culture--adapted SIVmac251 ([@bib18]).

### Flow cytometric analysis.

Whole blood, PBMC, LN, BAL, and small intestinal mucosa cells were obtained and stained for flow cytometric analysis as previously described ([@bib25]; [@bib23]). Polychromatic (8--12 parameter) flow cytometric analysis was performed on an LSR II instrument using Pacific blue, AmCyan, FITC, PE, PE--Texas red, PE-Cy7, PerCP-Cy5.5, APC, APC-Cy7, and Alexa Fluor 700 as the available fluorescent parameters. To evaluate FoxP3 expression, whole blood was obtained and stained with anti-CD3-A700, CD4-AmCyan, CD8-PerCP-Cy5.5, CD28.2-PE--Texas red, CD95-PE-Cy7, CCR7-Biotin--Pacific blue, and CD25-APC antibodies, fixed and permeabilized using the FoxP3 whole blood staining kit (eBioscience), and then stained with FoxP3-PE and Ki-67-FITC. Instrument set-up and data acquisition procedures were performed as previously described ([@bib31]). List mode multiparameter data files were analyzed using FlowJo software. Criteria for delineating naive and memory T cell subsets and for setting + versus − markers for CCR5 and Ki-67 expression have been previously described in detail ([@bib25]; [@bib23]; [@bib9]). In brief, T~N~ constitute a uniform cluster of cells with a CD28^moderate^, CCR7^+^, CCR5^−^, CD95^low^ phenotype, which is clearly distinguishable from the phenotypically diverse memory population that is CD95^high^ or displays one or more of the following non-naive phenotypic features: CD28^−^, CCR7^−^, or CCR5^+^. The T~CM~, T~TrEM~, and T~EM~ cell components of the memory subset in the blood and LNs were further delineated based on the following phenotypic criteria: T~CM~ (CD28^+^, and CCR7^+^ and CCR5^−^), T~TrEM~ (CD28^+^, and CCR7^−^ and/or CCR5^+^), and T~EM~ (CD28^−^, and CCR7^−^ and CCR5^dim^). For each subset to be quantified, the percentages of the subset within the overall small lymphocyte and/or small T cell (CD3^+^ small lymphocyte) populations were determined. For quantification of peripheral blood subsets, absolute small lymphocyte counts were obtained using an AcT5diff cell counter (Beckman Coulter) and, from these values, absolute counts for the relevant subset were calculated based the subset percentages within the light scatter--defined small lymphocyte population on the flow cytometer. Results (absolute subset counts after CD4^+^ cell depletion or after SIV infection) are presented as percentage of baseline, with baseline determined as the mean of values determined at days −14, −7, and 0 relative to the first dose of huOKT4A or to SIV challenge. For quantification in tissue, the fraction of the relevant subset within the overall T cell compartment after depletion or after SIV challenge was directly normalized to the baseline fraction, and the results were presented as percentage of baseline. For LN and intestinal biopsies, only one baseline sample was available.

### Statistical analysis.

Repeated measures ANOVA was used to investigate the effect of thymectomy versus sham surgery on T cell reconstitution after mAb huOKT4-mediated CD4^+^ T cell depletion, and the effects of CD4^+^ T~N~ deficiency on pvl and T cell subset/response dynamics after SIV infection. First order autoregressive covariance structure was used to account for within-subject correlation. Bonferroni's multiple comparison adjustment for preplanned contrasts was applied to secure overall type I error, whereas false discovery rate method for multiple comparison adjustment was applied for pairwise comparisons to avoid over-adjustment. Wilcoxon rank sum tests were used to compare the difference between CD4^+^ naive-repleted RMs and unmanipulated RMs in pvl (peak and day 70 pi), CD4^+^ T~M~ depletion (blood and BAL), CD4^+^ T~M~ proliferative response (blood), and the magnitude of SIV-specific CD8^+^ T cell responses at day 70 pi (blood and BAL) and to compare pre-challenge frequencies of RhCMV-specific CD4^+^ T cells between the CD4^+^ naive-depleted and -repleted RMs. The log-rank test was used to compare the survival distributions between CD4^+^ T~N~-depleted and -repleted RMs along the Kaplan-Meier curve. Logistic regression was used to access a difference in the fraction of RMs in each group manifesting measureable SIVenv-specific Ab titers by day 70 pi (binary outcome: responder vs. nonresponder). Permutation test was used to compare the statistical significance difference of CD4^+^/CD8^+^ ratios within the T cell memory populations in blood and selected secondary lymphoid tissues (axillary and inguinal LNs and spleen) and effector sites (liver, BAL, and small intestinal mucosa) of four out of five CD4^+^ T~N~-depleted and four out of four CD4^+^ T~N~-repleted RMs. Statistical significance was determined at the significance level of 0.05. These analyses were conducted using the Statistical Analysis System version 9.2 software.
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